MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Adaptive Biotechnologies Corp

Slēgts

7.47 0.67

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.28

Max

7.6

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.6M

-34M

Pārdošana

1M

47M

EPS

-0.228

Peļņas marža

-71.044

Darbinieki

619

EBITDA

-1.8M

-26M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+29.15% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-56M

1.1B

Iepriekšējā atvēršanas cena

6.8

Iepriekšējā slēgšanas cena

7.47

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Adaptive Biotechnologies Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. apr. 22:38 UTC

Karstas akcijas

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

2025. g. 4. apr. 21:53 UTC

Tirgus saruna

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

2025. g. 4. apr. 21:44 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

2025. g. 4. apr. 21:00 UTC

Top Ziņas

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

2025. g. 4. apr. 20:52 UTC

Tirgus saruna

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

2025. g. 4. apr. 20:52 UTC

Top Ziņas

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

2025. g. 4. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. apr. 20:48 UTC

Top Ziņas

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

2025. g. 4. apr. 20:45 UTC

Top Ziņas

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

2025. g. 4. apr. 20:32 UTC

Top Ziņas

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

2025. g. 4. apr. 20:21 UTC

Top Ziņas

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

2025. g. 4. apr. 20:00 UTC

Top Ziņas

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

2025. g. 4. apr. 19:51 UTC

Tirgus saruna

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

2025. g. 4. apr. 19:37 UTC

Top Ziņas

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

2025. g. 4. apr. 19:32 UTC

Tirgus saruna

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

2025. g. 4. apr. 19:28 UTC

Top Ziņas

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

2025. g. 4. apr. 19:15 UTC

Tirgus saruna

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

2025. g. 4. apr. 19:12 UTC

Top Ziņas

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

2025. g. 4. apr. 19:11 UTC

Tirgus saruna

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

2025. g. 4. apr. 19:09 UTC

Tirgus saruna

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

2025. g. 4. apr. 19:09 UTC

Top Ziņas

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

2025. g. 4. apr. 19:00 UTC

Tirgus saruna

Fed Has Limited Options to Counter Tariffs -- Market Talk

2025. g. 4. apr. 18:53 UTC

Tirgus saruna

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

2025. g. 4. apr. 18:51 UTC

Tirgus saruna

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

2025. g. 4. apr. 18:44 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 4. apr. 18:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 4. apr. 18:44 UTC

Tirgus saruna

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

2025. g. 4. apr. 18:43 UTC

Iegādes, apvienošanās, pārņemšana

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

2025. g. 4. apr. 18:43 UTC

Iegādes, apvienošanās, pārņemšana

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

2025. g. 4. apr. 18:39 UTC

Tirgus saruna

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Salīdzinājums

Cenas izmaiņa

Adaptive Biotechnologies Corp Prognoze

Cenas mērķis

By TipRanks

29.15% augšup

Prognoze 12 mēnešiem

Vidējais 9.57 USD  29.15%

Augstākais 12 USD

Zemākais 7 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Adaptive Biotechnologies Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

6

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

7.1126 / 7.67Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Weak Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.